OGEN 1.25
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OGEN 1.25 (OGEN 1.25).
Estrogen replacement therapy; binds to estrogen receptors (ERα and ERβ), modulating gene transcription and exerting effects on reproductive tissues, bone density, and cardiovascular system.
| Metabolism | Hepatic metabolism via CYP3A4; undergoes enterohepatic recirculation; primarily excreted as conjugates in urine. |
| Excretion | Renal: 95% (as glucuronide and sulfate conjugates); biliary/fecal: ~5% |
| Half-life | Terminal elimination half-life: 10–24 hours (mean ~15 h); clinically, steady-state achieved in 5–7 days |
| Protein binding | 98–99% bound to albumin and sex hormone-binding globulin (SHBG) |
| Volume of Distribution | Vd: 1.5–2.0 L/kg; distributes widely into tissues including breast, bone, and reproductive organs |
| Bioavailability | Oral: 30–50% due to first-pass metabolism; transdermal: 100% |
| Onset of Action | Oral: 2–4 weeks for full therapeutic effect on vasomotor symptoms; estrogenic effect on vaginal epithelium detectable within 2 weeks |
| Duration of Action | Duration: 24–48 hours for single-dose effects; continuous dosing required for sustained symptom relief |
| Molecular Weight | 272.38 |
1.25 mg orally once daily for 3 weeks, followed by a 1-week rest period; cyclic therapy.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment provided; use with caution in severe renal impairment. |
| Liver impairment | No specific dose adjustment provided; use with caution in severe hepatic impairment. |
| Pediatric use | Not indicated for use in pediatric patients. |
| Geriatric use | No specific dosage adjustment; initiate at the lowest effective dose and monitor for adverse effects. |
| 1st trimester | Contraindicated due to risk of fetal harm; estrogens can cause teratogenic effects. |
| 2nd trimester | Contraindicated; may cause urogenital abnormalities and other adverse outcomes. |
| 3rd trimester | Contraindicated; potential for fetal toxicity and complications. |
Clinical note
Comprehensive clinical and safety monograph for OGEN 1.25 (OGEN 1.25).
| Placental transfer | Estrogens cross the placenta and have been associated with fetal harm. |
| Breastfeeding | Estrogens are excreted in breast milk and may reduce milk production and quality; use is not recommended during breastfeeding. |
| Lactation Rating |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease or dementia. Increased risk of endometrial cancer, stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction in postmenopausal women. Increased risk of breast cancer with combined estrogen-progestin therapy.
| Serious Effects |
Known or suspected pregnancyUndiagnosed abnormal genital bleedingKnown or suspected breast cancer (except appropriately selected patients)Known or suspected estrogen-dependent neoplasiaActive or history of venous thromboembolismActive or history of arterial thromboembolic diseaseKnown hypersensitivity to estrogens or any component of the formulation
| Precautions | Cardiovascular disorders: increased risk of stroke, DVT, PE, MI, Malignant neoplasms: endometrial cancer (unopposed estrogen), breast cancer (with progestin), Gallbladder disease, hypercalcemia, Hepatic impairment, cholestatic jaundice, Hereditary angioedema, hypothyroidism, elevated triglycerides, Retinal vascular thrombosis, fluid retention, Dementia (increased risk in women ≥65 years) |
| Food/Dietary |
Loading safety data…
| Avoid |
| Teratogenic Risk | Estropipate, an estrogen, increases risk of fetal harm, including congenital anomalies and urogenital tract abnormalities, especially with first-trimester exposure. Use is contraindicated in pregnancy. Second- and third-trimester exposure may cause feminization of male fetuses and long-term reproductive tract effects in females. |
| Fetal Monitoring | Monitor for signs of thromboembolism, hypertension, and hypercalcemia. Perform regular prenatal ultrasounds to assess fetal growth and anatomy due to increased risk of anomalies. |
| Fertility Effects | Estrogen use may impair fertility by suppressing ovulation and altering endometrial receptivity. Discontinuation may resume normal menstrual cycles and fertility. |
| No specific food interactions; consistent intake of calcium and vitamin D recommended for bone health. |
| Clinical Pearls | Start with lowest effective dose; monitor for endometrial hyperplasia if uterus intact; avoid use in pregnancy (Category X); consider transdermal route for venous thromboembolism risk. |
| Patient Advice | Take with food to reduce gastrointestinal upset. · Notify prescriber if vaginal bleeding occurs. · Do not take if pregnant or planning pregnancy. · Report signs of blood clots (chest pain, leg swelling). |